Search Results - "Han, Kelong"

Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer by CLARET, Laurent, GUPTA, Manish, HAN, Kelong, JOSHI, Amita, SARAPA, Nenad, JING HE, POWELL, Bob, BRUNO, René

“…To assess new metrics of tumor-size response to predict overall survival (OS) in colorectal cancer (CRC) in Western and Chinese patients. Various metrics of…”
Get full text

Construction of carbonate reservoir knowledge base and its application in fracture-cavity reservoir geological modeling by HE, Zhiliang, SUN, Jianfang, GUO, Panhong, WEI, Hehua, LYU, Xinrui, HAN, Kelong

“…To improve the efficiency and accuracy of carbonate reservoir research, a unified reservoir knowledge base linking geological knowledge management with…”
Get full text

Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies by Youssef, Amir S., Ismail, Mohamed, Han, Kelong, Magee, Mindy, Nader, Ahmed

“…Introduction Bepirovirsen is a novel antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection therapy. Understanding the impact…”
Get full text

Population Pharmacokinetics of Cyclosporine in Transplant Recipients by Han, Kelong, Pillai, Venkateswaran C., Venkataramanan, Raman

“…A number of classical pharmacokinetic studies have been conducted in transplant patients. However, they suffer from some limitations, for example, (1) the…”
Get full text

Pharmacokinetics of oseltamivir among pregnant and nonpregnant women by Beigi, Richard H., MD, MSc, Han, Kelong, PhD, Venkataramanan, Raman, PhD, Hankins, Gary D., MD, Clark, Shannon, MD, MMS, Hebert, Mary F., PharmD, Easterling, Thomas, MD, Zajicek, Anne, MD, PharmD, Ren, Zhaoxia, MD, PhD, Mattison, Donald R., MD, Caritis, Steve N., MD

“…We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of…”
Get full text

Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients by Han, Kelong, Bies, Robert, Johnson, Heather, Capitano, Blair, Venkataramanan, Raman

“…Objectives: The objectives of this study were to evaluate the pharmacokinetics of voriconazole in liver transplant patients, probe covariate effects on…”
Get full text

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial by Han, Kelong, Jin, Jin, Maia, Mauricio, Lowe, John, Sersch, Martina A., Allison, David E.

“…Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC). We aim to evaluate bevacizumab pharmacokinetics in AGC from the…”
Get full text

Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Study by Krown, Susan E, Roy, Debasmita, Lee, Jeannette Y, Dezube, Bruce J, Reid, Erin G, Venkataramanan, Raman, Han, Kelong, Cesarman, Ethel, Dittmer, Dirk P

“…PURPOSE:The mammalian target of rapamycin is activated in Kaposi sarcoma (KS) and its inhibitor, rapamycin, has induced KS regression in transplant-associated…”
Get full text

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine by Patel, Parul, Teichner, Paula, Elliot, Emilie, Boffito, Marta, Murray, Milena, Polli, Joseph W., Baker, Mark, Ford, Susan L., Han, Kelong, Russu, Alberto, Crauwels, Herta, D’Amico, Ronald D., Spreen, William R., van Wyk, Jean

“…Cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting (LA) injectable regimen recommended by treatment guidelines for the maintenance of…”
Get full text

Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients by HAN, K, CAPITANO, B, BIES, R, POTOSKI, B. A, HUSAIN, S, GILBERT, S, PATERSON, D. L, MCCURRY, K, VENKATARAMANAN, R

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV" by Han, Kelong

Get full text

A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects by Han, Kelong, Cremer, Jennifer, Elston, Robert, Oliver, Stuart, Baptiste‐Brown, Sharon, Chen, Shuguang, Gardiner, David, Davies, Matt, Saunders, Joanne, Hamatake, Robert, Losos, Jan, Leivers, Martin, Hood, Steve, Berg, Frans, Paff, Melanie, Ritter, James M., Theodore, Dickens

“…GSK3389404 is a liver‐targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This…”
Get full text

Model‐Based Estimates of Tumor Growth Inhibition Metrics Are Time‐Independent: A Reply to Mistry by Claret, L, Han, K, Bruno, R

Get full text

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A by Han, K, Claret, L, Piao, Y, Hegde, P, Joshi, A, Powell, JR, Jin, J, Bruno, R

“…To simulate clinical trials to assess overall survival (OS) benefit of bevacizumab in combination with chemotherapy in selected patients with gastric cancer…”
Get full text

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region by Han, Kelong, Ito, Hiroshi, Elston, Robert, Cremer, Jennifer, Hood, Steve, Paff, Melanie, Theodore, Dickens

“…GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men by Han, Kelong, Wannamaker, Paul, Lu, Hongzhou, Zhu, Biao, Wang, Meixia, Paff, Melanie, Spreen, William R, Ford, Susan L

“…Long-acting (LA) cabotegravir demonstrated superior efficacy versus daily oral standard-of-care for HIV-1 preexposure prophylaxis. This phase 1 study assessed…”
Get full text

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants by Han, Kelong, Gevorkyan, Hakop, Sadik Shaik, Jafar, Crauwels, Herta, Leemereise, Claudia, Bontempo, Gilda, Win, Beta, Chounta, Vasiliki, Seal, Ciara, DeMoor, Rebecca, D'Amico, Ronald, Spreen, William R, Ford, Susan L

“…Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete long-acting (LA) regimen approved for maintaining HIV-1…”
Get full text

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects by Han, Kelong, Baker, Mark, Lovern, Mark, Paul, Prokash, Xiong, Yuan, Patel, Parul, Moore, Katy P., Seal, Ciara S., Cutrell, Amy G., D'Amico, Ronald D., Benn, Paul D., Landovitz, Raphael J., Marzinke, Mark A., Spreen, William R., Ford, Susan L.

“…Aim To characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic…”
Get full text

Population pharmacokinetics of bevacizumab in cancer patients with external validation by Han, Kelong, Peyret, Thomas, Marchand, Mathilde, Quartino, Angelica, Gosselin, Nathalie H., Girish, Sandhya, Allison, David E., Jin, Jin

“…Background Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of…”
Get full text

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials by Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A

“…The aim of this study was to determine correlations between progression-free survival (PFS) and the objective response rate (ORR) with overall survival (OS) in…”
Get full text